# Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL

> **NCT06832267** · NA · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 44 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT)

## Key facts

- **NCT ID:** NCT06832267
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-14
- **Primary completion:** 2027-02-13
- **Final completion:** 2028-02-13
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06832267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06832267, "Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06832267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*